Feb. 19 at 7:55 PM
$SLS $ABBV Gps is getting the FDA Green light to treat 12,500 AML CR2/3 patients Each year with an ad-infinite dosing regime.
- Co Published min. Estimated Pricing
$280K Per patient
- Just AML CR2/3
$3.5B Year 1 -
$5B in Year 2+
-- This alone is worth
$20B to Big Pharma.
Add in AML CR1 / and Post Transplant 40,000 Patients
- Each Year @
$280K $11.2B in Year 1.
$16.7B in Year 2.
- Plus there are an estimated 100,000 AML Patients Currently in Remission - who will Immediately benefit from and be Eligible for GPs immunotherapy upon Approval.
Gps will Set Records for patient uptake rates - 4x Survival advantage, near 100% Quality of Life, easy administration, high margin low cost manufacture, storage - Ip Rights into 2037, FDA/Eu Orphan and Fast Track - Rare Priority Review Designation.
This Manipulated Share price is offering the Investment of a Lifetime.
@yG19 you may want to update your model, i saw you used 3,000Cr2 patients and 6,000 Cr1 patients each year.
